Skip to Main content Skip to Navigation
Journal articles

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

Abstract : Epigenetic dysregulation has long been recognized as a key factor contributing to tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of cancer. Despite regulatory approvals for the treatment of certain haematological malignancies, the efficacy of the first generation of epigenetic drugs (epi-drugs) in patients with solid tumours has been disappointing; however, successes have now been achieved in selected solid tumour subtypes, thanks to the development of novel compounds and a better understanding of cancer biology that have enabled precision medicine approaches. Several lines of evidence support that, beyond their potential as monotherapies, epigenetic drugs could have important roles in synergy with other anticancer therapies or in reversing acquired therapy resistance. Herein, we review the mechanisms by which epi-drugs can modulate the sensitivity of cancer cells to other forms of anticancer therapy, including chemotherapy, radiation therapy, hormone therapy, molecularly targeted therapy and immunotherapy. We provide a critical appraisal of the preclinical rationale, completed clinical studies and ongoing clinical trials relating to combination therapies incorporating epi-drugs. Finally, we propose and discuss rational clinical trial designs and drug development strategies, considering key factors including patient selection, tumour biomarker evaluation, drug scheduling and response assessment and study end points, with the aim of optimizing the development of such combinations.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-02371032
Contributor : Geneviève Almouzni Connect in order to contact the contributor
Submitted on : Wednesday, December 9, 2020 - 1:34:25 PM
Last modification on : Tuesday, October 19, 2021 - 11:00:29 AM
Long-term archiving on: : Wednesday, March 10, 2021 - 6:19:49 PM

File

Morel D_Jeffery D_2019.pdf
Explicit agreement for this submission

Licence


Copyright

Identifiers

Citation

Daphné Morel, Daniel Jeffery, Sandrine Aspeslagh, Geneviève Almouzni, Sophie Postel-Vinay. Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise. Nature Reviews Clinical Oncology, Nature Publishing Group, 2019, 17 (2), pp.91-107. ⟨10.1038/s41571-019-0267-4⟩. ⟨hal-02371032⟩

Share

Metrics

Record views

111

Files downloads

580